← Return to Hormone Therapy (ADT) when ArteraAI Test says it's not necessary

Discussion
Comment receiving replies
Profile picture for tjnoffy @tjnoffy

@jim18 Some of what you're asking here I don't know. I'm drinking from a fire hose, as I'm sure everyone here has at the outset. Here is what I do know from the ArteraAI test:
10-YEAR RISK OF DISTANT METASTASIS: LOW group (not INTERMEDIATE), 2.4% risk
10-YEAR RISK OF PROSTATE CANCER SPECIFIC MORTALITY: 1.1%
COMPARISON OF THIS PATIENT TO THOSE IN SAME NCCN RISK GROUP: 28th percentile
ST-ADT BIOMARKER: Negative
Looking at the drawn map of the biopsy, two of 13 biopsy sites were Gleason 7 (4+3), one was Gleason 7 (3+4)
I don't see any indication of a Decipher test, and a Prostox Std test has not been mentioned.

Jump to this post


Replies to "@jim18 Some of what you're asking here I don't know. I'm drinking from a fire hose,..."

@tjnoffy You will probably need to ask for Decipher and Prostox Std tests if you want them. Decipher specifically estimates the probability of recurrence. It is covered by Medicare and uses biopsy tissue. With the ArteraAI risk being so low it might not add much. The Prostox Std test is designed to separate those at high risk of having long term (occur 8 months to years after treatment and are more permanent) GU effects from radiation such as ED, urethra constriction, etc. If high on Prostox risk is 75% of having 1 or more long term GU effects. If in the 86% not high the risk is 7%. The quoted risk is usually 15% so the test knocks out those at highest risk. Also, you may want to reconsider treatment plan if in high-risk group to either RP or SBRT (< 2% are high risk for both). Looks at 21 biomarkers responsible for repairing DNA, responding to stress and inflammation. This test was developed at UCLA but just became commercialized this year. Probably not covered by insurance. Maximum out of pocket $395 or lower based on income.